| Objective To investigate the efficacy and safety of anlotinib combined with tegio in the second-line treatment of advanced esophageal cancer. Methods From June 2018 to September 2019, 60 patients with advanced esophageal cancer who failed first-line chemotherapy or progressed after remission were selected in Chaohu Hospital of Anhui Medical University. They were randomly divided into observation group and control group with 30 cases in each group. The observation group was given the combination of anlotinib and tegio regimen, and the control group was given the single drug tegio regimen. The efficacy was evaluated every two cycles. The response rate (ORR), disease control rate (DCR) and median progression free survival (PFS) were compared. At the same time, the adverse reactions such as fatigue, hypertension, gastrointestinal reaction, hand foot skin reaction, oral mucositis, bone marrow suppression, liver function damage and proteinuria were analyzed.Results The ORR of observation group was 23.3% (7/30) and that of control group was 10.0% (3/30); there was no significant difference between the two groups (P>0.05). In observation group, DCR was 76.7% (23/30), PFS was 5.6 months. In control group, DCR was 46.7% (14/30) and PFS was 1.4 months. There were significant differences in DCR and PFS between the two groups (P<0.05). The incidence of hypertension in observation group was higher than that in control group (P<0.05), and there was no significant difference in other adverse reactions between the two groups (P>0.05). All adverse reactions could be relieved after symptomatic treatment.Conclusions The combination of tegio regimen and anlotinib has better efficacy and tolerable adverse reactions in the second-line treatment of advanced esophageal cancer,which is worth clinical promotion. |
